Journal article
A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial
Abstract
Recent evidence demonstrated CIN4 as a predictive marker of anthracycline benefit in early breast cancer. An analysis of the NCIC CTG MA.21 clinical trial was performed to test the role of existing CIN gene expression signatures as prognostic and predictive markers in the context of taxane based chemotherapy.RNA was extracted from patients in cyclophosphamide, epirubicin and flurouracil (CEF) and epirubicin, cyclophosphamide and paclitaxel …
Authors
Spears M; Lyttle N; D'Costa A; Chen BE; Yao CQ; Boutros PC; Burnell M; Levine MN; O'Brien P; Shepherd L
Journal
Oncotarget, Vol. 7, No. 31, pp. 49099–49106
Publisher
Impact Journals
Publication Date
August 2, 2016
DOI
10.18632/oncotarget.8542
ISSN
1949-2553
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAnthracyclinesAntibiotics, AntineoplasticAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantChromosomal InstabilityCyclophosphamideDisease-Free SurvivalEpirubicinFemaleFluorouracilGene Expression ProfilingHumansMiddle AgedPaclitaxelPrognosisTaxoids